The logic of the discovery begins with Huntington’s disease itself. The disorder is caused by an abnormal expansion of CAG trinucleotide repeats in the Huntingtin gene, which encodes an elongated poly-glutamine tract at the beginning of the protein. This expanded stretch drives misfolding, and the misfolded protein forms aggregates that disrupt transcription, intracellular transport, metabolism and, crucially, the ubiquitin-proteasome system, the cellular machinery responsible for shredding damaged or unwanted proteins. In patients, the chymotrypsin-like and caspase-like activities of the proteasome are measurably reduced in the striatum and cortex, the very brain regions that atrophy as the disease progresses. Eliminating the aggregates, therefore, has long been considered one of the most promising directions for therapy, but the question of how to do it safely has remained open.

MicroRNAs offered a tantalizing lead. These short non-coding RNAs regulate gene expression by binding to the 3′ untranslated regions of target messenger RNAs, blocking translation and thereby suppressing protein production. In the central nervous system, they tune everything from neurotransmitter receptors to ion channels, and several have documented neuroprotective effects in stroke, Alzheimer’s and Parkinson’s models. miR-196a had already earned attention in Huntington’s research: previous work from the same group showed that it improves neuronal morphology through the RANBP10 and IGF2 pathways, exerts antioxidant effects via the USP15/NRF2 axis, and, most strikingly, reduces mutant huntingtin aggregates and rescues pathological phenotypes in cell, mouse and induced pluripotent stem cell models. Yet the huntingtin gene contains no miR-196a binding sites, leaving the mechanism behind the aggregate reduction a genuine mystery.

To solve it, the team turned to unbiased proteomics. They transfected mouse neuroblastoma N2a cells with a fluorescent mutant huntingtin fragment containing 84 glutamine repeats, together with either miR-196a or a irrelevant control microRNA, and then analyzed the entire proteome by liquid chromatography-tandem mass spectrometry. Of 2,681 proteins identified, 147 rose and 144 fell significantly in the miR-196a-treated cells. Applying progressively stricter fold-change cutoffs and intersecting the results with five independent microRNA target-prediction databases, the researchers narrowed the field to six candidates. Western blot validation confirmed that two of them, Rad23b and Snap91, were significantly downregulated by miR-196a, and Rad23b, with its known ties to proteasome function, became the focus.

Confirming direct regulation came next. The researchers cloned the 3′ untranslated region of Rad23b downstream of a luciferase reporter and showed that miR-196a markedly suppressed luciferase activity, an effect abolished when the predicted binding site was mutated. The relationship held in living animals as well: cerebral cortex from miR-196a transgenic mice showed a moderate but significant reduction in Rad23b protein. Meanwhile, analysis of a public RNA sequencing dataset from directly reprogrammed striatal neurons revealed that Rad23b mRNA was significantly elevated in neurons derived from symptomatic Huntington’s patients compared with presymptomatic carriers, hinting that Rad23b tracks with disease progression rather than merely correlating with the mutation itself.

The functional experiments that followed delivered the study’s central surprise. When the researchers overexpressed Rad23b alongside mutant huntingtin in N2a cells, aggregates flourished, both the insoluble clumps and the soluble protein rose on Western blots, and cell death, measured by propidium iodide staining, climbed significantly. Conversely, knocking Rad23b down with short hairpin RNA or deleting it entirely using CRISPR-Cas9 shrank the aggregates dramatically. The effect was not an artifact of the fluorescent tag: untagged mutant huntingtin behaved the same way. When Rad23b was reintroduced into cells already treated with miR-196a, the microRNA’s suppressive effect on aggregates was reversed, establishing Rad23b as a key mediator of miR-196a’s neuroprotection.

Structural dissection explained how Rad23b physically engages the toxic protein. Fluorescently tagged Rad23b formed puncta that colocalized with huntingtin aggregates in cultured cells, and endogenous Rad23b did the same in the cortex and striatum of Huntington’s transgenic mice, while remaining evenly distributed in healthy animals. Co-immunoprecipitation confirmed a direct physical interaction in both directions. Mutating any of the three lysine residues at positions 6, 9 and 15 in the N-terminus of huntingtin, the likely sites of ubiquitination, reduced the Rad23b-driven aggregation, and deleting both of Rad23b’s ubiquitin-associated domains abolished its effect, pinpointing the ubiquitin-binding machinery as the critical interface.

The mechanism, however, turned out to be darker than a simple shuttle-to-destruction story. Rad23b is classically described as an ubiquitin shuttle protein, using its ubiquitin-like domain to dock at the proteasome and its ubiquitin-associated domains to ferry ubiquitinated cargo for degradation. Consistent with that role, Rad23b overexpression increased the ubiquitination of mutant huntingtin. Yet the ubiquitinated protein was not destroyed. A reporter assay using a destabilized GFP substrate revealed that Rad23b-deficient cells degraded proteasomal cargo faster than wild-type cells, and direct enzymatic measurements showed that deleting Rad23b significantly boosted the chymotrypsin-like activity of the proteasome, the very activity that is depressed in the brains of Huntington’s patients. Inhibiting the proteasome with MG132 restored aggregates in Rad23b-knockout cells, whereas blocking autophagy with chloroquine had no effect, confirming that the pathway in play is the ubiquitin-proteasome system, not autophagy. In short, Rad23b tags huntingtin for destruction but simultaneously gums up the destruction machinery, a molecular sabotage that tips the balance toward accumulation.

The in vivo evidence sealed the case. The team generated Rad23b transgenic mice by lentiviral transgenesis and crossed them with R6/2 Huntington’s mice, which carry an N-terminal human huntingtin fragment with 120 to 150 CAG repeats. The resulting double-transgenic animals fared measurably worse than their Huntington’s littermates: at eight and nine weeks of age they fell off an accelerating rotarod sooner and at lower speeds, and they showed elevated hindlimb clasping scores, a classic sign of worsening motor dysfunction. Biochemical analysis of the cortex at six weeks revealed significantly more mutant huntingtin aggregates in the double transgenics, and immunofluorescent staining of the retrosplenial cortex showed Rad23b-labeled aggregates accompanied by significantly more TUNEL-positive dying cells. Neither Rad23b nor miR-196a transgene expression alone produced any Huntington-like pathology, underscoring that Rad23b acts by amplifying the mutant protein’s toxicity rather than causing disease on its own.

The implications reach beyond Huntington’s disease. Rad23b has been found sequestered in neuronal inclusions across a striking range of disorders, including spinocerebellar ataxias, frontotemporal dementia, amyotrophic lateral sclerosis and Parkinson’s disease, yet its role appears context-dependent: in C9ORF72-linked disease, restoring Rad23b actually reduces poly-glycine-alanine aggregates. The authors suggest their mechanism fits poly-glutamine aggregates specifically, and they caution that bulk cortical lysates may dilute neuron-specific proteasomal changes, that behavioral testing here focused on motor readouts, and that miR-196a likely acts through multiple pathways, including metabolic ones hinted at by their proteomic enrichment analyses. Even so, the conclusion is compelling: downregulating Rad23b, or disrupting its interaction with mutant huntingtin, offers a concrete, mechanistically grounded strategy to clear toxic aggregates and slow disease progression, potentially applicable across the family of poly-glutamine disorders. For a disease that has resisted every therapeutic attempt for decades, a small RNA with a well-defined target is exactly the kind of lead the field has been waiting for.

Subject of Research: miR-196a-mediated suppression of Rad23b to reduce mutant huntingtin aggregates through the ubiquitin-proteasome system in Huntington's disease

Article Title: miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington’s disease

Article References: Tung, C.-W., Chan, S. C., Chen, Y.-C., Wu, P.-M., Cheng, P.-H., Chen, C.-M., & Yang, S.-H. (2026). miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington’s disease. Journal of Biomedical Science, 33(1), Article 90. https://doi.org/10.1186/s12929-026-01292-5

Image Credits: AI Generated

DOI: 10.1186/s12929-026-01292-5

Keywords: Huntington's disease, miR-196a, Rad23b, mutant huntingtin, protein aggregates, ubiquitin-proteasome system, microRNA, neurodegeneration, proteomics, R6/2 transgenic mice, chymotrypsin-like activity, gene regulation